Vadivarhe Speciality Chemicals Ltd (VSCL) Share Price & Fundamentals

What we do

Vadivarhe Speciality Chemicals Ltd manufactures specialty chemicals, active pharmaceutical ingredients, intermediates, and personal care products for global pharmaceutical and chemical sectors.

Founded in

2,009

Market share

Serves leading pharmaceutical companies domestically and internationally, building reputation through quality certifications like WHO-GMP and ISO.

Problem solved

Provides high-quality, certified specialty chemicals and APIs addressing global pharmaceutical manufacturing needs.

Top clients or who we serve

Clients include GlaxoSmithKline, Lupin Ltd, USV Ltd; serves B2B pharmaceutical and chemical industries globally.

Key management

Executive Director Mr. Sunil Haripant Pophale leads with extensive industry experience.

Our journey and innovations

Started with API production in 2010; IPO raised ₹14.46 Cr in 2017; expanded API portfolio significantly by FY2025.

Where we operate

India and international markets including UK and US clients.

Top products or what we offer

Specialty chemicals, Active Pharmaceutical Ingredients (APIs), intermediates, and personal care products.

Top brands

WHO-GMP certified APIs, specialty chemical divisions serving global pharma leaders.

Raw materials needed

Organic chemicals and specialty chemical inputs for API and intermediates production.

Raw materials supplier

Details undisclosed; sourced to maintain quality and regulatory compliance.

Recurring vs cyclical contribution

Revenue primarily recurring with long-term contracts from pharmaceutical clients.

Our industry position

Recognized supplier in specialty chemicals with quality certifications, catering major Indian and global pharma firms.

Financial highlights

FY2025 Revenue ₹38.17 Cr; net loss ₹9.27 Cr; prior year ₹40.57 Cr revenue and ₹0.06 Cr profit.

Geographical revenue split

India contributes approximately 74%, outside India about 26% of revenue.

Order book

-

Whats driving growth

Expanding API production capacity, strong client relationships, and focus on quality standards.

Our future plans

Increase API commercial production and explore new specialized chemical offerings.

Our green promise

Committed to energy conservation and environmental safety measures in manufacturing.

Our people and values

75 employees; emphasis on talent development, ethical practices, and diversity.

Key challenges ahead

Profitability recovery, market competition, and regulatory compliance remain key challenges.

Interesting facts

Company evolved from Fem Care Pharma Ltd division taken over from Dabur India Ltd.

Risks and strategy

Mitigates risks with quality certifications and diversification across pharma chemicals.